Reading Time: < 1 minute

BENSALEM, Pa.–(BUSINESS WIRE)–lt;a href=”” target=”_blank”gt;$BSXlt;/agt; lt;a href=”” target=”_blank”gt;#classactionlt;/agt;–Law Offices of Howard G. Smith announces an investigation on behalf of
Boston Scientific Corporation (“Boston Scientific” or the “Company”)
investors concerning the Company and its officers’ possible violations
of federal securities laws.

On April 16, 2019, the Company was ordered by the U.S. Food and Drug
Administration (“FDA”) to stop selling and distributing its surgical
mesh products. According to the FDA, the Company had “not demonstrated a
reasonable assurance of safety and effectiveness for these devices.”

On this news, the Company’s share price fell $2.90 per share, more than
7%, over the following two trading sessions to close at $34.91 per share
on April 17, 2019, thereby injuring investors.

If you purchased Boston Scientific securities, have information or would
like to learn more about these claims, or have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Howard G. Smith, Esquire, of Law Offices of
Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania
19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by
email to [email protected],
or visit our website at

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.


Law Offices of Howard G. Smith
Howard G. Smith, Esquire
[email protected]